
    
      This is a single center , single arm, phase II study. All eligible patients with the de novo
      metastatic NPC are treated with chemotherapy plus subsequent loco-regional radiotherapy
      combined with toripalimab. The primary objective of this study is to assess objective
      response rate of chemotherapy plus subsequent loco-regional radiotherapy combined with
      toripalimab in de novo metastatic nasopharyngeal carcinoma . The secondary objective is to
      assess progression free survival, and Adverse events.
    
  